Literature DB >> 1864455

Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions.

S Hunskaar1, D Donnell.   

Abstract

Orphenadrine citrate, a monomethylated derivative of diphenhydramine, has been used as a muscle relaxant and as an analgesic both alone or as a constituent of combination products. Data on the efficacy of orphenadrine alone and in combination with paracetamol for painful conditions are evaluated in the present review. From the available animal data it is concluded that the antinociceptive effect of orphenadrine has been clearly demonstrated but data have also clearly indicated that it has muscle relaxant properties. Human placebo-controlled studies have shown some support for the view that orphenadrine on its own acts as a mild analgesic in painful conditions associated with muscle spasm. Although only a small number of well-controlled studies have been completed with the combination product of orphenadrine/paracetamol, each supports the view that the combination has superior efficacy over paracetamol alone. There is no doubt that the combination product is more efficacious than placebo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864455     DOI: 10.1177/030006059101900201

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  10 in total

1.  Acute angle closure glaucoma presented with nausea and epigastric pain.

Authors:  Evangelos Cholongitas; Chrysoula Pipili; Maria Dasenaki
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

2.  Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies.

Authors:  J Kornhuber; C G Parsons; S Hartmann; W Retz; S Kamolz; J Thome; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats.

Authors:  Katherine L Nicholson; Robert L Balster
Journal:  Psychopharmacology (Berl)       Date:  2003-07-08       Impact factor: 4.530

Review 4.  Electroencephalography and analgesics.

Authors:  Lasse Paludan Malver; Anne Brokjaer; Camilla Staahl; Carina Graversen; Trine Andresen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

5.  The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study.

Authors:  Pål Gjerden; Jørgen G Bramness; Lars Slørdal
Journal:  Br J Clin Pharmacol       Date:  2008-12-16       Impact factor: 4.335

6.  Orphenadrinium picrate.

Authors:  Jerry P Jasinski; Ray J Butcher; B P Siddaraju; H S Yathirajan; B Narayana
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-12-18

7.  Orphenadrinium picrate picric acid.

Authors:  Hoong-Kun Fun; Madhukar Hemamalini; B P Siddaraju; H S Yathirajan; B Narayana
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-02-24

8.  A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition.

Authors:  Kit Yee Cheah; Kar Yee Mah; Lai Hui Pang; Shi Min Ng; Jia Woei Wong; Siew Siew Tan; Hong Zhe Tan; Kah Hay Yuen
Journal:  BMC Pharmacol Toxicol       Date:  2020-06-23       Impact factor: 2.483

9.  Clinical Response of Nuberol Forte® for Pain Management With Musculoskeletal Conditions in Routine Pakistani Practice (NFORTE-EFFECT).

Authors:  Syed Shahid Noor; Muhammad Kazim Najjad; Nasir Ahmed; Khurram Anwar; Abdul Memon; Tehseen Riaz; Muhammad Hanif; Nauman Maqbool; Saeed Ahmed; Israr Ahmed; Ali Yasir Khanzada
Journal:  Cureus       Date:  2022-03-09

10.  Orphenadrinium dihydrogen citrate.

Authors:  Manpreet Kaur; Jerry P Jasinski; Amanda C Keeley; H S Yathirajan; B P Siddaraju
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-01-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.